Andy Barker

415 total citations
9 papers, 309 citations indexed

About

Andy Barker is a scholar working on Organic Chemistry, Oncology and Molecular Biology. According to data from OpenAlex, Andy Barker has authored 9 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Organic Chemistry, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Andy Barker's work include Oxidative Organic Chemistry Reactions (2 papers), Advanced Breast Cancer Therapies (2 papers) and Mast cells and histamine (2 papers). Andy Barker is often cited by papers focused on Oxidative Organic Chemistry Reactions (2 papers), Advanced Breast Cancer Therapies (2 papers) and Mast cells and histamine (2 papers). Andy Barker collaborates with scholars based in United Kingdom. Andy Barker's co-authors include Jason G. Kettle, J. Elizabeth Pease, Thorsten Nowak, Kevin I. Booker‐Milburn, Andrew P. Thomas, A Rutman, Robert Wilson, Alexandra McGregor, David Watson and Robert W. Wilkinson and has published in prestigious journals such as Journal of Applied Physiology, Tetrahedron and Tetrahedron Letters.

In The Last Decade

Andy Barker

9 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andy Barker United Kingdom	6	133	99	87	70	27	9	309
Kin‐Chun Luk United States	10	202 1.5×	113 1.1×	125 1.4×	26 0.4×	23 0.9×	15	342
Lijiao Wang China	10	157 1.2×	67 0.7×	97 1.1×	54 0.8×	16 0.6×	24	334
Estelle G. McLean United Kingdom	5	271 2.0×	177 1.8×	100 1.1×	24 0.3×	21 0.8×	7	479
Xuechi Lin China	10	216 1.6×	113 1.1×	40 0.5×	66 0.9×	9 0.3×	11	381
Álvaro Lorente‐Macías Spain	6	165 1.2×	60 0.6×	95 1.1×	24 0.3×	41 1.5×	15	345
Mridula Misra India	9	162 1.2×	66 0.7×	76 0.9×	28 0.4×	8 0.3×	20	403
Weijie Gao China	12	247 1.9×	76 0.8×	108 1.2×	29 0.4×	28 1.0×	15	388
John A. Lupisella United States	11	249 1.9×	54 0.5×	25 0.3×	51 0.7×	9 0.3×	14	408
Greta Klejborowska Poland	11	154 1.2×	32 0.3×	96 1.1×	116 1.7×	12 0.4×	19	333
F Pellegrini Italy	3	134 1.0×	73 0.7×	133 1.5×	44 0.6×	11 0.4×	8	319

Countries citing papers authored by Andy Barker

Since Specialization

Citations

This map shows the geographic impact of Andy Barker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Barker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Barker more than expected).

Fields of papers citing papers by Andy Barker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Barker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Barker. The network helps show where Andy Barker may publish in the future.

Co-authorship network of co-authors of Andy Barker

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Barker. A scholar is included among the top collaborators of Andy Barker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Barker. Andy Barker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Barker, Andy, Jason G. Kettle, Thorsten Nowak, & J. Elizabeth Pease. (2012). Expanding medicinal chemistry space. Drug Discovery Today. 18(5-6). 298–304. 69 indexed citations

2.

Byth, Kate F., Andrew P. Thomas, Gareth Hughes, et al.. (2009). AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Molecular Cancer Therapeutics. 8(7). 1856–1866. 104 indexed citations

3.

Luke, Richard, Ed Griffen, Neil J. Hales, et al.. (2009). In vitro pharmacological profiles of kinase inhibitors: Comparison with other pharmaceuticals. Journal of Pharmacological and Toxicological Methods. 60(2). 219–219. 1 indexed citations

4.

Kettle, Jason G., et al.. (2004). N‐Benzylindole‐2‐carboxylic Acids: Potent Functional Antagonists of the CCR2b Chemokine Receptor.. ChemInform. 35(16). 1 indexed citations

5.

Kettle, Jason G., et al.. (2003). N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor. Bioorganic & Medicinal Chemistry Letters. 14(2). 405–408. 24 indexed citations

6.

Booker‐Milburn, Kevin I., et al.. (1998). Diastereoselective Fe(III) mediated oxidative cyclisation reactions of cyclopropanone acetals. Tetrahedron Letters. 39(24). 4373–4376. 8 indexed citations

7.

Gibson, Keith H., Andrew A. Godfrey, J.R. Woodburn, et al.. (1998). ChemInform Abstract: Epidermal Growth Factor Receptor Tyrosine Kinase: Structure—Activity Relationships and Antitumor Activity of Novel Quinazolines.. ChemInform. 29(8). 4 indexed citations

8.

Booker‐Milburn, Kevin I., et al.. (1998). Fe(III) mediated oxidative radical cyclisation of cyclopropanone acetals. Tetrahedron. 54(50). 15321–15344. 31 indexed citations

9.

Munro, N C, Andy Barker, A Rutman, et al.. (1989). Effect of pyocyanin and 1-hydroxyphenazine on in vivo tracheal mucus velocity. Journal of Applied Physiology. 67(1). 316–323. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact